IBS Flashcards
define IBS
recurren abdominal pain or discomfort at least 3 days per month in last 3 months associated with:
improvement with defacation, onset associated with a change in stool frequency and appearance
subtypes of IBS based on the predominant stool pattern
with constipation
with diarrhea
mixed
unsubtypes
IBS pathophys
nervous system(brain gut interactions)
gut flora issues (post infection, bacterial overgrowth)
altered sensitivity to gut distention altered signal processes in the cns
altered motor response
alarm features
weight loss >5kg bloody stool severe diarhea recurring fever over 50 (rare for onset to be in elderly) family histoyr of colon cancer and IBD
what quides therapeutic plans
predominant symptoms
constipation, diarrhea, pain, bloating, gas
sources of constipation to look for
low fibre, lack of exercise, meds, decreased abdominal pressure, metabolic abnormalities
sources of diarrhea to look for
food
lactose
sorbitol
fructose
non pharms
establish therapeutic relationship with patient
regulate dietary intake
avoid precipitants
avoid excess - carbonated drinks, gum, caffiene
behavioural therapies
relax biofeedback hypnotherpay CBT psychotherapyu
how long does i take to assess efficacy of treatment
3-4 weeks
treatment for IBS with constipation
fiber based products osmotic and salt laxatives stimulant laxatives prucalopride linaclotide
fibre based products MOA
increase stool bulk and frequency
increase GI transit time
reduce gas by binding bile salts
benefit of fiber based products
not much better than placebo
best in abdominal pain and constipation
how to initiate psyllium
1tsp per day and increase 3-5 days
up ro 1-2 tsp 3 times a day or more
examples of osmotic and salt laxatives
lactulose (AE:gas, bloating, taste)
magnesium
phosphate
PEG based
describe stimulant laxatives
senna based , bisacodyl
quick onset
AE: cramping
dont cause colon dysfunction
how to approach laxatives
start with regimen as a regular routine then change from there
prucalopride MOA
serotonin 4 receptor agonist
lower affinity for hERG
stimulates colonic transit
prucalopride indication
chronic idiopathic constipation in females with inadequate response to laxatives
prucalopride disadvantage
renally cleared
not for pregnancy
nausea diarrhea, headache dose related
not covered
linaclotide MOA
peptide guanylate cyclse C agonist
indirectly activates cystic fibrosis transmembrane conductance regulator
secretion of CI and bicarb into bowel and increased transit